GMAB News and Press, Genmab A/S From 09/23/20

AC Immune SA (ACIU) -43% as semorinemab flunks Alzheimer's study.Wave Life Sciences (WVE) -31% after pricing equity offering.Aurora Cannabis (ACB) -17% on soft revenue outlook.NanoVibronix (NAOV) -17% after increasing the size of the previous publi...

Genmab (GMAB) down 12% premarket in reaction to the announcement that it was locked in a legal battle with its partner Johnson & Johnson (JNJ) over royalty payments for its key cancer drug, source Reuters.Yesterday, GMAB commenced binding arbitration of two matters under license...

Healthcare players such as Regeneron Pharmaceuticals (REGN), Genmab (GMAB), Horizon Therapeutics (HZNP), and Bio-Rad Laboratories (BIO) demonstrated high-profit margins and are expected to witness a surge in their earnings, revenue, and profit margins with the advent of a definitive vaccine for...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...

The FDA approves the use of Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's Darzalex (daratumumab) to treat adults with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy. More news on: Johnson & Johnson, Genmab A/S, Healthcare s...

Genmab A/S (NASDAQ: GMAB ) will receive a $30M payment from licensee Novartis (NYSE: NVS ) to account for lost royalties from blood cancer med Arzerra (ofatumumab). More news on: Genmab A/S, Novartis AG, Healthcare stocks news, Read more ...

Written by Nick Ackerman, co-produced by Stanford Chemist We last visited BlackRock Health Sciences Trust II ( BMEZ ) only a couple of months after its launch in January. Several months have passed, and this fund has been performing exceptionally well. While it has only been a few months...

The following slide deck was published by Genmab A/S in conjunction with their 2020 Q2 earnings Read more ...

Genmab A/S (GMAB) Q2 2020 Results Conference Call August 12, 2020 12:00 PM ET Company Participants Jan van de Winkel - President & CEO Anthony Pagano - CFO Judith Klimovsky - CDO Anthony Mancini - EVP & COO Conference Call Participants Peter Verdult - Citi Wimal...

Image source: The Motley Fool. Genmab A/S   (NASDAQ: GMAB) Q2 2020 Earnings Call Aug 12, 2020 , 12:00 p.m. ET Operator Continue reading